Long interspersed nuclear element-1 (L1) retrotransposons are normally suppressed in somatic tissues mainly by DNA methylation and antiviral defense. However, L1s can be desuppressed in cancers to act as insertional mutagens and cause genomic instability by creating DNA double strand breaks and chromosomal rearrangements. Whereas the frequency of somatic L1 insertions varies greatly among individual tumors, much remains to be learned about underlying genetic, cellular, or environmental factors. Here, our pan-gastrointestinal cancer genome analyses for stomach, colorectal, and esophageal tumors identified multiple correlates of L1 activity. Clinical indicators of tumor progression, such as tumor grade and patient age, showed positive association. Potential L1 expression suppressors such as TP53 and DNMT1, a DNA methyltransferase, were inactivated in tumors with frequent L1 insertions. Importantly, tumors with high immune activity, for example, due to viral infection or high tumor-antigen load, tended to carry a low number of L1 insertions in their genomes with high expression levels of L1 suppressors such as APOBEC3s and SAMHD1. Our analysis of the transcriptional effects of intragenic retrotransposon insertions demonstrated an increased risk of gene disruption in retrotransposition-prone cancers. In particular, we found a splicing-disrupting L1 insertion in an exon of MOV10, a key L1 suppressor, which caused exon skipping with evidence of nonsensemediated decay in a tumor with a high L1 insertion load. Our results indicate that cancer immunity may contribute to genome stability by suppressing L1 retrotransposition particularly in gastrointestinal cancers.
INTRODUCTION
Frequent desuppression and retrotransposition of the long interspersed nuclear element-1 (LINE-1 or L1) have been reported in multiple cancer types (Lee et al. 2012; Solyom et al. 2012; Helman et al. 2014; Tubio et al. 2014) . Notably, gastrointestinal cancers, including esophageal (Doucet-O'Hare et al. 2015; Secrier et al. 2016 ), gastric (Ewing et al. 2015 , and colorectal cancers (Lee et al. 2012; Solyom et al. 2012) , reportedly carry extensive somatic L1 insertions.
The rate of L1 insertions varies substantially among individual tumors, ranging from a few to hundreds. Clinical and molecular factors identified in association with L1 insertions include patient age in colorectal cancer (Solyom et al. 2012) , patient survival in pancreatic cancer (Rodic et al. 2015) , and TP53 mutations in head and neck cancer (Helman et al. 2014 ). However, further investigation is needed on the mechanisms underlying these associations. Furthermore, previous studies may have been limited in their ability to detect other factors, especially those related to major L1 suppression mechanisms, namely DNA methylation and antiviral defense, due to small sample sizes and/or lack of matched expression profiles. L1 insertions are able to disrupt target gene function by interrupting protein-coding sequences or altering mRNA splicing and expression. Intragenic somatic L1 insertions previously identified in cancer genomes were depleted in exons and mostly located in introns, generally decreasing target gene expression (Lee et al. 2012; Helman et al. 2014) with some exceptions (Helman et al. 2014 ).
On the other hand, Tubio et al. analyzed 24 expression profiles from TCGA lung and colon cancer samples and reported no evidence of altered gene expression and aberrant transcripts caused by somatic L1 insertions (Tubio et al. 2014) . Although aberrant splicing is a major pathogenic mechanism of retrotransposon insertions causing Mendelian disorders and hereditary cancers (Hancks and Kazazian 2016) , to our knowledge, no somatic L1 insertions have been reported in association with splicing alterations in sporadic human cancers.
Here, we analyzed whole genome sequencing data for which somatic retrotransposition had not previously been investigated, and which were obtained from cancer patients of three gastrointestinal cancer types using an improved version of Tea (Transposable Element Analyzer) (Lee et al. 2012 ). Among other findings, our analysis identified cancer immunity as the most prominent variable that explained variation in retrotransposition rates among individual tumors.
We identified exon skipping caused by somatic retrotransposon insertions and found a significant downregulation of genes with somatic L1 insertions, corroborating the high gene disrupting potential of somatic retrotransposition in cancer.
RESULTS

Highly variable frequency of somatic L1 insertions in gastrointestinal cancers
We applied Tea (Transposable Element Analyzer) (Lee et al. 2012) with improved 3' transduction (i.e., mobilization of unique non-L1 DNA downstream of the L1) detection to the whole-genome sequencing data of tumor and blood samples from a total of 189 gastrointestinal cancer patients across three cancer types: 95 stomach (40 TCGA and 55 non-TCGA (Wang et al. 2014)), 62 TCGA colorectal, and 32 esophageal (19 TCGA and 13 non-TCGA (Dulak et al. 2013 )) cancer patients. We detected 3,885 somatic L1 insertions with target site duplication (TSD) and polyA tails ( Supplemental Table S1 and S2), the two signatures for target-primed reversed transcription (TPRT)-mediated retrotransposition. While the insertion frequency varied greatly, most (89%) samples carried at least one insertion with the average number of insertions at 21 ( Fig. 1a and Supplemental Table S3 ), thereby confirming previous findings that gastrointestinal cancers are highly susceptible to somatic L1 retrotransposition (Burns 2017) . Out of 137 insertions with 3' transduction, more than a half (56%) were derived from two germline L1s on chromosome X and 22 (Xp22.2 and 22q12.1) ( Fig. 1b and Supplemental Table S2 ), consistent with a previous finding that a handful of source L1s generated most 3' transductions in cancers (Tubio et al. 2014) . 1,192 (31%) of the 3,885 L1 insertions were found in gene bodies-mostly in introns (29%, Fig.   1c ). A total of 210 genes, including known (LRP1B and PTPRT) and putative cancer driver genes were affected by somatic L1 insertions in multiple cancer samples ( Fig. 1d) . For example, ROBO1, an emerging tumor suppressor (Gara et al. 2015; Huang et al. 2015) , had at least one somatic L1 insertion in each of seven cancer samples (two stomach and five colorectal samples).
PARK2, a master regulator of G1/S cyclins that is frequently deleted in cancers (Gong et al. 2014) , was marked by one insertion in each of six samples (one stomach, three colorectal, and two esophageal samples). Genes with recurrent somatic L1 insertions (Fig. 1d) , including ROBO1, PTPRT, GRID2, CDH8, CDH12, CDH13, PTPRM, ROBO2, were enriched for brain development and function including axon guidance, neuron differentiation, and synaptic function ( Supplemental Table S4 ). However, this could be attributed to the fact that neuronal genes tend to be long (Zylka et al. 2015) . Indeed, no significant enrichment was found after adjusting for gene size, suggesting the overall absence of positive selection of cancer cells with somatic L1 insertions.
Cancer immune activity negatively correlated with somatic L1 retrotransposition
We then wanted to understand mechanisms underlying the variable frequency of L1 insertions in cancers. First, we examined the association of L1 insertions with molecular markers or clinical traits. We observed a significant association of TP53 mutation status with the L1 insertion rate.
Somatic L1 insertions were more frequent in tumors with TP53 mutations than those with wildtype TP53 (P = 0.004, Fig. 2a ). This corroborates the recent implication of TP53 in restraining L1 transcription (Wylie et al. 2016 ). When we examined whether any aberration in DNA repair pathways could be associated with L1 retrotransposition, only the p53 repair pathway showed a significant association (P = 6.3 x 10 -3 , see Methods for details). Regarding associations with tumor grade and patient age, more frequent somatic L1 insertions were observed in cancers at an advanced stage (P = 0.043, Fig. 2b ) and in older stomach cancer patient samples (P = 0.054, Fig.   2c ). We found a positive correlation between L1 insertion frequency and the expression level of L1 itself (P = 0.0052, Fig. 2d ) and a negative correlation with the expression level of DNMT1, a DNA methyltransferase (r = -0.31, P = 7.2 X 10 -4 ). These associations suggest that aberrant L1 transcription potentially induced by DNA methylation loss and mutations in L1 transcription suppressors is a prerequisite to frequent retrotransposition in cancer.
We then performed a more systematic transcriptome analysis by measuring the transcriptional activity of 1,789 pathways from the Reactome database (Milacic et al. 2012; Fabregat et al. 2016) in 112 TCGA cancer samples with RNA-seq profiles, using the single-sample GSEA (ssGSEA) method (Subramanian et al. 2005) . A total of 50 and 97 pathways showed positive and negative correlations, respectively, with L1 insertion counts ( Fig. 3a and Supplemental Table S5 , FDR < 0.05). Notably, 49 out of 176 (28%) immune pathways showed significant negative correlations. For example, cancers with active interferon alpha/beta signaling carried fewer somatic L1 insertions ( Fig. 3b , r = -0.42, P = 4.6 x 10 -6 ). To further test the relationship between L1 insertions and immune activity, we used fifteen annotated sets of immune genes (Breuer et al. 2013; Rooney et al. 2015) . Our analysis showed consistent negative correlations, especially in stomach cancer (Fig. 3c) , thereby supporting a robust immunological association of L1
retrotransposition. Finally, we tested 13 genes that are known to act as L1 inhibitors (Goodier 2016). We found significant negative correlations for AICIDA, SAMHD1, and APOBEC3C/D/F/H (Fig 3d) . Since several L1 inhibitors, such as MOV10 and APOBEC3 family proteins, are known to be activated by type I interferons (IFNs) (Yu et al. 2015) , it is likely that active interferon alpha/beta signaling may suppress L1 retrotransposition by activating L1 suppressors.
Characterization of cancer subgroups with differential immune activity
Based on the 49 L1-associated immune pathways in 112 cancer samples, we identified two distinct cancer subgroups for stomach/esophageal cancer (SE; SE-High and SE-Low) and colorectal cancer (CRC; CRC-High and CRC-Low) that differed in their immune signatures ( Fig.   3e ). Somatic L1 insertions were significantly less frequent in the high immune activity subgroups ( Fig. 3e and Fig 4a , P = 7.3 x 10 -5 and P = 2.1 x 10 -2 for SE and CRC, respectively). The expression levels of two cytotoxic T cell effector genes (GZMA and PRF1) (Rooney et al. 2015) indicated consistent and significant differential cytolytic activity between the subgroups (Supplemental Fig. S1a , P = 6.4 × 10 -7 and P = 2.9 × 10 -4 for SE and CRC, respectively).
Interestingly, adaptive immune pathways showed more differential activities between the subgroups than innate immune and cytokine signaling pathways (Supplemental Fig. S2 and Supplemental Table S6 ). For example, 'immunoregulatory interactions between a lymphoid and a non-lymphoid cell' was one of the most differential pathways (FDR = 6.9 x 10 -7 and 8.5 x 10 -7 for SE-High vs SE-Low and CRC-High vs CRC-Low, respectively). In fact, this pathway includes multiple receptors and cell adhesion molecules, such as KIRs and LLIRs, that play a key role in regulating immune cell responses to tumor-antigens. PD-1 signaling is another adaptive immune pathway with significant differential activity between the subgroups (FDR = 1.5 x 10 -6 and 6.6 x 10 -7 for SE-High vs SE-Low and CRC-High vs CRC-Low, respectively).
We next investigated features that could be a potential determinant of immune activity. First, (Davoli et al. 2017) . Indeed, the degree of copy number changes significantly differed according to immune activity ( Fig. 4c ), suggesting the copy number alteration of immune-related genes as another determinant of immune activity (Gao et al. 2016) . We also note that mutant TP53 was associated with low immune activity ( Fig. 4d) , consistent with previous findings that TP53 dysfunction leads to immunosuppression (Rooney et al. 2015; Cui and Guo 2016) . This result highlights the crucial role of TP53 in restricting retrotransposons as a guardian of L1 expression ( Fig. 2a and Supplemental Fig. S1c ) and immune integrity ( Fig. 4d) .
Some cancers may exhibit weak immune activity due to the immune suppressive effect of IFNsignaling, possibly triggered by persistent L1 expression. INF signaling is known to be immune stimulatory, but its persistent activation can trigger immune suppression, especially in the presence of chronic viral infection (Minn and Wherry 2016). Thus, elevated L1 expression mainly caused by DNA hypomethylation and/or TP53 mutations might activate IFN-signaling as an L1 suppression mechanism (Yu et al. 2015) ; however, its persistent activation might shift its role to immune suppressor, leading to weakened L1 suppression and thus increased L1 retrotransposition.
L1 insertions disrupting mRNA splicing and expression
Finally, we wanted to examine the effect of intragenic L1 insertions on transcriptional regulation.
To this end, we analyzed matched RNA-sequencing data from 112 TCGA cancer samples for which genomes were analyzed for L1 insertions. Briefly, we calculated the ratio of abnormally spliced RNA-seq reads to normally spliced reads near a somatic L1 insertion and evaluated whether the ratio was significantly higher than expected given the ratio distribution estimated from RNA-seq profiles of control samples without the given insertion.
We screened 1192 intragenic L1 insertions with matched RNA-seq profiles and found skipping of exon 20 of MOV10, a known L1 suppressor, with a somatic L1 insertion in one esophageal cancer sample (Fig. 5a) . The cancer sample carried 65 somatic L1 insertions and belonged to the low immune group. MOV10 is known to suppress L1 expression and decrease cytoplasmic L1RNPs (Goodier et al. 2012) . The exon skipping event caused by the insertion is likely to have disrupted the MOV10 function through multiple mechanisms, including the creation of premature termination codons (PTC) followed by nonsense-mediated decay (NMD). We hypothesized that if an L1 insertion triggers NMD, we might observe decreased expression of transcripts with the insertion allele. Since it is hard to distinguish RNA-seq reads from an L1 insertion allele, we used heterozygous single-nucleotide variants (SNVs) to assess allele-specific down-regulation of Recent work has reported that L1s tend to insert into lowly expressed genes (Tubio et al. 2014) .
We thus investigated the expression level of genes with somatic L1 insertions in our data. Out of 809 expressed genes (mean TPM > 0 per cancer type) with one or more somatic L1 insertions, 167 (21%) and 111 (14%) genes expressed at a moderate (TPM 10~100) and high (TPM ≥ 100) level, respectively (Supplemental Fig. S3 ). This shows that one-third of all intragenic insertions have the potential to alter target gene expression levels. To test this possibility, we next compared the expression level of genes with L1 insertions with the expression level of the same genes in cancer samples without L1 insertions and non-synonymous mutations in the genes. Our analysis revealed that L1 insertions significantly disrupt the expression of target genes in all cancer types, consistent with our previous finding (Lee et al. 2012) (Fig. 5d ). The significant decrease in gene expression level was observed even when excluding 300 genes that were expressed at a very low level (TPM <1). Decreased levels of expression in genes with somatic L1 insertions may be due in part to the NMD process triggered by PTC-containing transcripts with abnormal splicing, as suggested above regarding MOV10.
DISCUSSION
It remains an open question whether transposable elements, particularly L1s, play a role in tumorigenesis and what factors determine variable L1 retrotransposition rates in tumors. Here, we analyzed ~200 cancer genomes from three types of gastrointestinal cancer samples and identified a large set of somatic L1 insertions. We found the insertions in some known cancer genes, including LRP1B, PTPRT, ROBO1, and PARK2, in multiple cancer samples. We performed an integrative analysis using RNA-seq profiles of these samples, and found that ~35% of somatic L1 insertions in genes were expressed at a moderate to high level and that they generally disrupted expression of target genes. We also detected somatic retrotransposon insertions causing splicing aberrations.
Although the number of somatic L1 insertions varied greatly in different samples, we detected high average rates of insertions in gastrointestinal cancer, consistent with previous reports. Our analysis identified multiple clinical correlates of somatic L1 retrotransposition in cancer including advanced patient age and tumor stage. TP53 mutations were frequently observed in cancers with a high rate of retrotransposition, supporting the function of TP53 as an L1
suppressor. In addition, we discovered a negative correlation between L1 insertion frequency and expression of a subset of known L1 suppressors, including specific APOBEC3 family proteins and SMAHD1, suggesting that they are dominant L1 suppressors in primary human tumors.
Notably, we found that immune activity of tumors is a major factor in explaining the L1 retrotransposition rate. Less L1 retrotransposition activity was found in tumors with high immune activity triggered largely by exogenous or endogenous immunogens such as EBV infection or unstable microsatellite repeats. Moreover, many L1 suppressor genes such as AID/APOBEC, cytidine deaminases, are downstream effector genes of INF and other immune pathways. Although strong immune response effectively suppresses L1 retrotransposition, the increased expression of some APOBECs may lead to extensive APOBEC-mediated mutagenesis, increasing the risk of cancer development (Roberts et al. 2013; Rebhandl et al. 2015) . Most importantly, when cancers have low immune activity led by such things as a high CNV load, immune gene aberration, TP53 mutation, or cancer treatment, they are prone to extensive L1 retrotransposition and thus are at increased risk of tumorigenic insertion events. Larger scale cancer genome analyses considering clinical, genetic, and environmental factors will further illuminate the role of transposable elements in cancer. B  a  r  b  i  e  D  A  ,  T  a  m  a  y  o  P  ,  B  o  e  h  m  J  S  ,  K  i  m  S  Y  ,  M  o  o  d  y  S  E  ,  D  u  n  n  I  F  ,  S  c  h  i  n  z  e  l  A  C  ,  S  a  n  d  y  P  ,  M  e  y  l  a  n  E  ,  S  c  h  o  l  l  C  e  t  a  l  .  2  0  0  9  .  S  y  s  t  e  m  a  t  i  c  R  N  A  i  n  t  e  r  f  e  r  e  n  c  e  r  e  v  e  a  l  s  t  h  a  t  o  n  c  o  g  e  n  i  c  K  R  A  S  -d  r  i  v  e  n  c  a  n  c  e  r  s  r  eu  i  r  e  T  B  K  1  . N a t u r e 4 6 2 
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Figure legend
METHODS
Whole genome sequencing data
We 
RNA sequencing and gene expression data
We obtained RNA sequencing bam files for 112 TCGA cancer samples from CGHub and genelevel expression data for the TCGA samples from the UCSC cancer genomics browser (https://genome-cancer.ucsc.edu/). For non-TCGA stomach cancer samples, we downloaded raw expression array data from the European Genome-phenome Archive (EGA; accession ID:
EGAD00010000528) and extracted gene-level expression data using the IlluminaExpressionFileCreator module in GenePattern (Reich et al. 2006) . For non-TCGA esophageal cancer samples, we downloaded gene-level expression data from the Gene Expression Omnibus (GEO; accession ID: GSE42363). We used ComBat (Johnson et al. 2007) to combine expression data from different studies for each cancer type.
Detection of somatic L1 insertions
We implemented a 3' transduction calling module in the previously developed transposon In order to be identified as an insertion, the insertion candidate must have had a poly-A tail and a target-site duplication (TSD) ranging from 5 bp to 35 bp long.
Partnered transduction
To detect an L1 insertion with 3' transduction, repeat-anchored mate (RAM) clusters obtained from Tea were paired with discordant read pair clusters generated by Meerkat (Yang et al. 2013 ).
For each discordant read pair cluster, we required each to be supported by at least three discordant read pairs. If a RAM cluster was paired with one of the ends from a discordant read pair cluster in positive and negative orientations and the distance between the ends of the clusters was within 1kb, then the two different clusters were merged to define an initial candidate. The remaining ends from the discordant read pair were used to infer the source of an L1 element. To remove false positives, RAM clusters paired with multiple discordant read pair clusters were filtered out. Contigs were assembled using clipped and discordant reads supporting an insertion event, and the assembled contigs were examined for the presence of poly-A tails and TSD.
Orphan transduction
For some L1 retrotransposition events with 3' transductions, 5' truncation can occur before the retrotransposition of the L1 sequence itself starts, leaving the insertion site with only the 3' transduction sequence but not the L1 sequence. This type of L1 insertion is defined as an orphan transduction (Tubio et al. 2014) . To detect such an event, we used discordant read pair clusters generated by Meerkat (Yang et al. 2013 ). Discordant read pair clusters supported by at least three reads were considered. Two different discordant clusters mapped within 1kb that support both sides of an insertion in the expected orientation were merged to define initial candidates. Clusters mapped with multiple clusters were filtered out. Contigs were assembled using clipped and discordant reads supporting an insertion candidate. The assembled contigs were examined for the presence of poly-A tails and TSD. We called an insertion candidate as an orphan transduction event when its source L1 element was identified as a reference L1HS-Ta, a non-reference germline L1, or a somatic L1 insertion.
Somatic SNV/indel and copy number aberration call sets
We generated somatic SNV and indel call sets for TCGA colorectal cancer samples using Mutect 
L1 expression quantification
Reads from RNA-sequencing data were aligned to an L1 sequence library using BWA (Li and The number of reads mapping to the L1 sequence was normalized by the total number of RNAseq reads.
Gene expression analysis
For each gene with a somatic L1 insertion, we calculated the difference between the expression level of the gene from the cancer sample with the insertion and the average expression level from cancer samples without any mutation in the gene. We then calculated the average of the expression differences for each cancer type. To calculate the P value of the observed average expression difference, we estimated a background distribution by using 10,000 randomly selected gene sets with the same number of genes as in our gene set having somatic L1 insertions for each cancer type. The empirical P value was calculated as the proportion of the random gene sets that produced an average expression difference that was less than the observed value.
Pathway activity analysis
We obtained a set of pathways from the Reactome database (Fabregat et al. 2016 
Gene set enrichment analysis
We tested if genes with somatic L1 insertions in more than one cancer sample were enriched in certain Gene Ontology (GO) terms in the biological process category. We used Goseq (Young et al. 2010) that allowed for adjustment of gene length bias and took as inputs the longest isoform length (the sum of the lengths of all unique exons and introns) for each gene. To identify DNA repair pathways associated with somatic L1 insertion frequency, we obtained 15 DNA repair pathways from a previous publication (Jeggo et al. 2016 ) and classified cancer samples into the mutant and wild-type groups depending on the presence of a non-synonymous mutation in any member gene for each pathway. We then compared L1 insertion frequencies between the two groups using the Mann-Whitney test.
Splicing analysis
To identify somatic L1 insertion-mediated abnormal splicing, we employed our previously established ratio-based approach to detect altered splicing caused by somatic mutations (Jung et al. 2015) . Specifically, we first extracted abnormally spliced reads near retrotransposon insertion loci and then calculated the ratio of abnormally spliced reads to total reads (the sum of normally and abnormally spliced reads). Uniquely aligned reads excluding PCR duplicates were subjected to this analysis. Next, we assessed whether the ratio was significantly higher than expected,
given the background distribution estimated from normal control samples and tumor samples (up to 111 TCGA tumor samples) that lacked non-synonymous mutations for a given gene. We obtained a total of 2,860 control normal RNA-seq data from the Genotype-Tissue Expression (GTEx) project (Consortium 2013). To confirm that the observed splicing change was caused by a somatic retrotransposon insertion, the observed ratio had to be within the top 1% of the background ratio distribution. We screened 69 additional TCGA cancer RNA-seq data to detect splicing aberration caused by somatic retrotransposon insertions reported in a previous study (Helman et al. 2014 ) .
Analysis of allelic expression of MOV10
We called SNVs in MOV10 from WGS and RNA-seq data from TCGA cancer samples using Signal transduction (327) Gene expression (151) Disease (443) Metabolism (308) Metabolism of proteins (104) Cell cycle ( (7) Macrophages (10) Neutrophils (10) NK cells (2) pDCs (10) MHC Class I (3) Co-stimulation, APC (11) Co-stimulation, T cell (13) Co-inhibition, APC (5) Co-inhibition, T cell (10) Type I IFN Reponse (10) Type II IFN Reponse (3) GZMA and PRF1 ( 
